Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.66 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.66 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.66 |
| ▸ | AURKA | O14965 | 1/20 | 0.66 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.66 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.66 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.66 |
| ▸ | PRKACA | P17612 | 1/20 | 0.66 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.66 |
| ▸ | CDK2 | P24941 | 1/20 | 0.66 |
| ▸ | MARK3 | P27448 | 1/20 | 0.66 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.66 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.66 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 8/20 | 0.57 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | CSF1R | P07333 | 1/20 | 0.54 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29529931 | 1.00 | PDPK1 (0.66) | PDPK1LRRK2CHEK1AURKACHEK2 | |
| Dimethyladenine SCHEMBL152594 | 0.79 | LRRK2 (1.00) | PDPK1LRRK2CHEK1AURKACHEK2 | |
| Dimethyladenine SCHEMBL29349831 | 0.79 | LRRK2 (1.00) | PDPK1LRRK2CHEK1AURKACHEK2 | |
| Dimethyladenine SCHEMBL11157548 | 0.78 | PDPK1 (0.96) | PDPK1LRRK2CHEK1AURKACHEK2 | |
| SCHEMBL30602928 | 0.76 | LRRK2 (0.73) | PDPK1LRRK2CHEK1AURKACHEK2 | |
| SCHEMBL6517686 | 0.76 | LRRK2 (0.73) | PDPK1LRRK2CHEK1AURKACHEK2 | |
| SCHEMBL30544086 | 0.76 | LRRK2 (0.67) | PDPK1LRRK2CHEK1AURKACHEK2 | |
| SCHEMBL9203283 | 0.75 | HTT (0.76) | PDPK1LRRK2CHEK1AURKACHEK2 | |
| SCHEMBL9096944 | 0.74 | HSD17B10 (0.69) | PDPK1LRRK2CHEK1AURKACHEK2 | |
| SCHEMBL401115 | 0.73 | CHEK1 (0.37) | PDPK1LRRK2CHEK1AURKACHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250378926-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-12378302-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20240360199-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2024-10-31 | — | — | US | disclosed |
| US-20240071588-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-11578372-B2 | NTRK1 fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| EP-3561077-B1 | METHODS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER LAB (FR) | 2022-12-21 | — | — | EP | disclosed |
| US-20220243280-A1 | NTRK FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-08-04 | — | — | US | disclosed |
| US-20100272721-A1 | TREATMENT OF CANCER | BIOGEN IDEC MA INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100113294-A1 | DEFINED GLYCOPROTEIN PRODUCTS AND RELATED METHODS | MOMENTA PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| EP-2137655-A1 | DEFINED GLYCOPROTEIN PRODUCTS AND RELATED METHODS | Momenta Pharmaceuticals, Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20080292622-A1 | METHODS OF EVALUATING PATIENTS | BIOGEN IDEC MA INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080279853-A1 | TREATMENT OF CANCER | BIOGEN IDEC MA INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008128230-A1 | REFERENCE GLYCOPROTEIN PRODUCTS AND RELATED METHODS | MOMENTA PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008128227-A1 | DEFINED GLYCOPROTEIN PRODUCTS AND RELATED METHODS | MOMENTA PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2007038264-A2 | GAPR-1 METHODS | BIOGEN IDEC MA INC. (US) | 2007-04-05 | — | — | WO | disclosed |
| WO-2006138219-A2 | METHODS OF DIAGNOSIS / PROGNOSIS OF INFLAMMATORY CONDITIONS | BIOGEN IDEC MA INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006130429-A2 | TREATMENT OF CANCER | BIOGEN IDEC MA INC. (US) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578372-B2 | NTRK1 fusion molecules and uses thereof | NTRK1, NTRK3, NTRK2 | PDPK1 698/4885LRRK2 1432/4885CHEK1 1558/4885 |
| US-20220243280-A1 | NTRK FUSION MOLECULES AND USES THEREOF | NTRK1, NTRK3, NTRK2 | PDPK1 1256/4885LRRK2 1905/4885CHEK1 2068/4885 |
| US-20250378926-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | PDPK1 4125/4885LRRK2 3143/4885CHEK1 476/4885 |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | PDPK1 3738/4885LRRK2 2879/4885CHEK1 4235/4885 |
| US-20240071588-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | PDPK1 4125/4885LRRK2 3143/4885CHEK1 476/4885 |
| US-20240360199-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | PDPK1 3738/4885LRRK2 2879/4885CHEK1 4235/4885 |
| US-12378302-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | PDPK1 3892/4885LRRK2 3220/4885CHEK1 4260/4885 |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | PDPK1 3738/4885LRRK2 2879/4885CHEK1 4235/4885 |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | PDPK1 3892/4885LRRK2 3220/4885CHEK1 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.